Extended-release Pharmacotherapy for Opioid Use Disorder
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is a clinical superiority effectiveness contrast to standard of care.
Reported following SPIRIT and CONSORT standards, the study will determine whether
extended-release injectable depot Buprenorphine (XR-Bup) maintenance therapy for OUD over six
months is clinically superior to standard-of-care, oral medication (sublingual Buprenorphine
[SL-Bup] or oral methadone [Met]; together: Bup/Met)
Phase:
Phase 3
Details
Lead Sponsor:
King's College London
Collaborators:
Bangor University Birmingham and Solihull Mental Health NHS Foundation Trust Cumbria, Northumberland Tyne and Wear NHS Foundation Trust Greater Manchester Mental Health NHS Foundation Trust NHS Tayside South London and Maudsley NHS Foundation Trust